The impact of COVID-19 infection on idiopathic pulmonary fibrosis mortality: a systematic review and meta-analysis DOI Creative Commons

Davide Cavasin,

Umberto Zanini, Laura Montelisciani

et al.

Monaldi Archives for Chest Disease, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 15, 2024

COVID-19 has a negative impact on the survival of respiratory patients, especially those with interstitial lung disease. This review aims to better understand effect patients idiopathic pulmonary fibrosis (IPF). A systematic search MEDLINE, PubMed, Embase, and Scopus performed from December 2019 up July 2024 identified relevant studies. Eligibility criteria included English language, sample size ≥10 infection outcome measures. Two independent reviewers assessed studies using Newcastle-Ottawa Scale for bias extracted data. Meta-analysis employed random-effects model, Grading Recommendations Assessment, Development Evaluation evidence quality. Outcomes considered were hospitalization, intensive care unit admission, mortality. Of 1541 initially articles, 6 high-quality included. revealed 34% mortality rate [95% confidence interval (CI): 21-48%], 36% hospitalization (95% CI: 10-75%), 31% ICU admission 7-71%) among IPF COVID-19. The certainty was low or very due publication heterogeneity. study underscores elevated risk death in COVID-19, emphasizing vulnerability this population. Prompt tailored is crucial mitigate necessitating proactive measures, vaccination, comprehensive management.

Language: Английский

A Nationwide Cohort Study of Delta and Omicron SARS-CoV-2 Outcomes in Vaccinated Individuals With Chronic Lung Disease DOI
Liang En Wee,

Janice Yu Jin Tan,

Calvin J. Chiew

et al.

CHEST Journal, Journal Year: 2024, Volume and Issue: 166(4), P. 685 - 696

Published: June 11, 2024

Language: Английский

Citations

5
The Saga of COVID-19 in Chronic Lung Disease: History Repeats Itself DOI
Amir Sharafkhaneh, Javad Razjouyan

Annals of the American Thoracic Society, Journal Year: 2024, Volume and Issue: 21(7), P. 1001 - 1002

Published: July 1, 2024

Language: Английский

Citations

0
Integration of GWAS and multi-omic QTLs identifies uncharacterized COVID-19 gene-biotype and phenotype associations DOI Creative Commons
Meritxell Oliva, Emily A. King, Reza Hammond

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 5, 2024

Abstract To better understand COVID-19 pathobiology and to prioritize treatment targets, we sought identify human genes influencing genetically driven disease risk severity, additional organismal-level phenotypes impacted by pleiotropic COVID-19-associated genomic loci. this end, performed ancestry-aware, trans-layer, multi-omic analyses integrating recent Host Genetics Initiative genome-wide association (GWAS) data from six ancestry endpoints - African, Amerindian, South Asian, East European meta-ancestry with quantitative trait loci (QTL) GWAS colocalization analyses. We identified colocalizations for 47 307 observed a highly variable (1-435 endpoint colocalizations) degree of pleiotropy per locus but high representation pulmonary traits. For those, directionality effect mapped pathological alleles pinpoints systematic protective effects COPD, detrimental lung adenocarcinoma, locus-dependent IPF. Among 64 QTL-COVID-19 colocalized loci, associations most reported (47/53) half unreported (19/38) including 9 in non-European cohorts. generated evidence metrics visualization tools, integrated pulmonary-specific QTL signal, aid the identification putative causal cells. example, among likely not previously linked COVID-19, desmoplakin-driven IPF-shared genetic perturbations alveolar Altogether, provide insights into biology identifying molecular phenotype links architecture severity phenotypes; further characterizing providing novel uncharacterized

Language: Английский

Citations

0
Influence of Bronchopulmonary Diseases on the Course and Outcome of COVID-19: a Literature Review DOI Creative Commons
Е Г Слесарева, Аndrey М. Sarana,

Sergey G. Sсherbak

et al.

Juvenis scientia, Journal Year: 2024, Volume and Issue: 10(4), P. 19 - 28

Published: Aug. 30, 2024

The SARS-CoV‑2 coronavirus has become a major global health concern. Infection with caused millions of deaths worldwide, and the case fatality rate been found to be largely related pre-existing clinical conditions. main manifestation COVID‑19 is presence respiratory symptoms. Severe complications are most often observed in people significant medical histories. virus primarily attacks system, causing pneumonia acute distress syndrome, which can lead severe systemic inflammation, multiple organ dysfunction, death, especially patients comorbidities. A number meta-analyses strongly suggest that comorbid diseases, including chronic obstructive pulmonary disease interstitial lung factors development forms COVID‑19, worsening patient outcomes survival rates. Studies have shown an association between adverse expression level angiotensin-­converting enzyme 2 (ACE2) these patients. Regarding other system pathologies, such as bronchial asthma cystic fibrosis, it known unfavorable factor long-term immunosuppressive pharmacotherapy preceding infection. In this article, we highlight comorbidities better understand pathogenesis COVID‑19.

Language: Английский

Citations

0
The impact of COVID-19 infection on idiopathic pulmonary fibrosis mortality: a systematic review and meta-analysis DOI Creative Commons

Davide Cavasin,

Umberto Zanini, Laura Montelisciani

et al.

Monaldi Archives for Chest Disease, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 15, 2024

COVID-19 has a negative impact on the survival of respiratory patients, especially those with interstitial lung disease. This review aims to better understand effect patients idiopathic pulmonary fibrosis (IPF). A systematic search MEDLINE, PubMed, Embase, and Scopus performed from December 2019 up July 2024 identified relevant studies. Eligibility criteria included English language, sample size ≥10 infection outcome measures. Two independent reviewers assessed studies using Newcastle-Ottawa Scale for bias extracted data. Meta-analysis employed random-effects model, Grading Recommendations Assessment, Development Evaluation evidence quality. Outcomes considered were hospitalization, intensive care unit admission, mortality. Of 1541 initially articles, 6 high-quality included. revealed 34% mortality rate [95% confidence interval (CI): 21-48%], 36% hospitalization (95% CI: 10-75%), 31% ICU admission 7-71%) among IPF COVID-19. The certainty was low or very due publication heterogeneity. study underscores elevated risk death in COVID-19, emphasizing vulnerability this population. Prompt tailored is crucial mitigate necessitating proactive measures, vaccination, comprehensive management.

Language: Английский

Citations

0